MannKind Corporation (NASDAQ:MNKD - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for MannKind in a research report issued on Wednesday, July 16th. HC Wainwright analyst forecasts that the biopharmaceutical company will post earnings of $0.05 per share for the quarter. HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for MannKind's current full-year earnings is $0.10 per share. HC Wainwright also issued estimates for MannKind's Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.05 EPS.
Other equities research analysts have also issued reports about the stock. Mizuho assumed coverage on shares of MannKind in a report on Thursday, April 10th. They set an "outperform" rating and a $12.00 price target for the company. Wall Street Zen raised shares of MannKind from a "hold" rating to a "buy" rating in a report on Friday. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $10.14.
View Our Latest Analysis on MNKD
MannKind Price Performance
MNKD stock traded up $0.06 on Friday, hitting $3.82. 2,615,386 shares of the company were exchanged, compared to its average volume of 2,433,538. MannKind has a twelve month low of $3.51 and a twelve month high of $7.63. The business's fifty day moving average is $4.02 and its two-hundred day moving average is $4.86. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 23.50 and a beta of 0.96.
MannKind (NASDAQ:MNKD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. The firm had revenue of $78.35 million for the quarter, compared to the consensus estimate of $75.86 million. MannKind had a net margin of 10.12% and a negative return on equity of 32.41%. The firm's revenue was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.05 earnings per share.
Insider Activity
In related news, Director Steven B. Binder sold 75,367 shares of the stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $3.94, for a total value of $296,945.98. Following the sale, the director directly owned 830,508 shares in the company, valued at $3,272,201.52. This trade represents a 8.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP David Thomson sold 32,179 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total transaction of $150,597.72. Following the completion of the sale, the executive vice president owned 772,427 shares in the company, valued at $3,614,958.36. This represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 266,198 shares of company stock worth $1,143,244. 3.00% of the stock is owned by insiders.
Hedge Funds Weigh In On MannKind
Several hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in MannKind during the 4th quarter valued at $37,000. Farther Finance Advisors LLC lifted its holdings in shares of MannKind by 1,379.2% during the second quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 6,896 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in shares of MannKind during the fourth quarter worth $65,000. Blueshift Asset Management LLC acquired a new position in MannKind in the first quarter valued at about $51,000. Finally, Proficio Capital Partners LLC acquired a new position in MannKind in the fourth quarter valued at about $70,000. 49.55% of the stock is owned by institutional investors.
About MannKind
(
Get Free Report)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Further Reading
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
